- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | HilleVax GAAP EPS of -$0.52 misses by $0.10 | 2 | Seeking Alpha | ||
| 07.11. | HilleVax, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | HilleVax, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | HilleVax kündigt Personalabbau zur Kostensenkung an | 1 | Investing.com Deutsch | ||
| HILLEVAX Aktie jetzt für 0€ handeln | |||||
| 16.10. | HilleVax announces workforce reduction to cut costs | 2 | Investing.com | ||
| 16.10. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.08. | HilleVax GAAP EPS of -$0.83 | 1 | Seeking Alpha | ||
| 09.08. | HilleVax, Inc.: HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress | 166 | GlobeNewswire (Europe) | $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine... ► Artikel lesen | |
| 01.08. | HilleVax slashes workforce by 40% after norovirus vaccine trial failure | 1 | Pharmaceutical Technology | ||
| 01.08. | HilleVax Lays Off 40% of Workforce | 1 | Contract Pharma | ||
| 01.08. | UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs | 4 | FierceBiotech | ||
| 31.07. | HilleVax, Inc.: HilleVax Announces Reduction in Force | 75 | GlobeNewswire (Europe) | BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce... ► Artikel lesen | |
| 31.07. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | HilleVax, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.07. | Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure | 1 | Zacks | ||
| 09.07. | (HLVX) - Analyzing HilleVax's Short Interest | 2 | Benzinga.com | ||
| 09.07. | Stifel cuts HilleVax to hold, price target to $3 on failed study | 2 | Seeking Alpha | ||
| 09.07. | HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails | 2 | Zacks | ||
| 08.07. | A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in Infants | 1 | MedCity News | ||
| 08.07. | Gold Falls Over 1%; HilleVax Shares Plunge | 5 | Benzinga.com |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,870 | -0,35 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,887 | +3,26 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| VIKING THERAPEUTICS | 49,390 | +0,96 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| AFFIMED | 2,610 | -0,38 % | Affimed N.V.: Affimed Reports Third Quarter 2024 Financial Results & Business Update | AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a... ► Artikel lesen | |
| GALAPAGOS NV | 23,680 | -1,50 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| CELLECTAR BIOSCIENCES | 1,480 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| CYTOMX THERAPEUTICS | 0,854 | +3,96 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| CYTOKINETICS | 48,000 | +1,27 % | Pharma-Offensive: Bayer schließt Millionen-Deal mit Cytokinetics - Rettung oder Risiko? | © Foto: picture alliance / Rupert Oberhäuser | Rupert OberhäuserBayer stärkt mit einem Millionen-Deal sein Herz-Kreislauf-Portfolio, doch Analysten bleiben skeptisch: Rechtsstreitigkeiten und Gewinne... ► Artikel lesen | |
| ATARA BIOTHERAPEUTICS | 10,690 | 0,00 % | Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress | THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to... ► Artikel lesen |
HILLEVAX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HILLEVAX INC finden Sie auf Wallstreet Online.
